Q-omics provides the consensus-scored LGALS12 profile across patient tissues and cancer cell-line models. LGALS12 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, LGALS12 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, LGALS12 RNA expression shows 11,894 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight OV, KIRC, and BRCA as cancer lineages where LGALS12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LGALS12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LGALS12 survival associations across molecular data types. LGALS12 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LGALS12 RNA expression–survival associations across cancer types. High LGALS12 expression shows unfavorable associations in OV, STAD, LGG and UCS, but favorable associations in HNSC and ESCA. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify OV as the clearest survival context for LGALS12 RNA expression.
This table summarizes LGALS12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LGALS12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LGALS12 shows lower tumor expression in BRCA, LUSC, HNSC, BLCA and LUAD and higher tumor expression in KIRC. The KIRC box plot shows higher LGALS12 RNA expression in tumor versus normal tissue (log2 FC = +1.797, t-test p < 0.001).
This table shows molecular features associated with LGALS12 in patient tissues and cancer cell lines. In patient samples, LGALS12 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, LGALS12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
